These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 39043643)

  • 21. CD8
    Chen Y; Xin Z; Huang L; Zhao L; Wang S; Cheng J; Wu P; Chai Y
    Front Immunol; 2019; 10():3002. PubMed ID: 32010126
    [No Abstract]   [Full Text] [Related]  

  • 22. NK cell expression of Tim-3: First impressions matter.
    So EC; Khaladj-Ghom A; Ji Y; Amin J; Song Y; Burch E; Zhou H; Sun H; Chen S; Bentzen S; Hertzano R; Zhang X; Strome SE
    Immunobiology; 2019 May; 224(3):362-370. PubMed ID: 30876792
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Indirect Impact of PD-1/PD-L1 Blockade on a Murine Model of NK Cell Exhaustion.
    Alvarez M; Simonetta F; Baker J; Morrison AR; Wenokur AS; Pierini A; Berraondo P; Negrin RS
    Front Immunol; 2020; 11():7. PubMed ID: 32117218
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Requirement for innate immunity and CD90⁺ NK1.1⁻ lymphocytes to treat established melanoma with chemo-immunotherapy.
    Moskalenko M; Pan M; Fu Y; de Moll EH; Hashimoto D; Mortha A; Leboeuf M; Jayaraman P; Bernardo S; Sikora AG; Wolchok J; Bhardwaj N; Merad M; Saenger Y
    Cancer Immunol Res; 2015 Mar; 3(3):296-304. PubMed ID: 25600438
    [TBL] [Abstract][Full Text] [Related]  

  • 25.
    Guo X; Mahlakõiv T; Ye Q; Somanchi S; He S; Rana H; DiFiglia A; Gleason J; van der Touw W; Hariri R; Zhang X
    J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33741730
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A humanized 4-1BB-targeting agonistic antibody exerts potent antitumor activity in colorectal cancer without systemic toxicity.
    Cheng LS; Cheng YF; Liu WT; Shen A; Zhang D; Xu T; Yin W; Cheng M; Ma X; Wang F; Zhao Q; Zeng X; Zhang Y; Shen G
    J Transl Med; 2022 Sep; 20(1):415. PubMed ID: 36076251
    [TBL] [Abstract][Full Text] [Related]  

  • 27. COM902, a novel therapeutic antibody targeting TIGIT augments anti-tumor T cell function in combination with PVRIG or PD-1 pathway blockade.
    Hansen K; Kumar S; Logronio K; Whelan S; Qurashi S; Cheng HY; Drake A; Tang M; Wall P; Bernados D; Leung L; Ophir E; Alteber Z; Cojocaru G; Galperin M; Frenkel M; White M; Hunter J; Liang SC; Kotturi MF
    Cancer Immunol Immunother; 2021 Dec; 70(12):3525-3540. PubMed ID: 33903974
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Natural killer cells produce T cell-recruiting chemokines in response to antibody-coated tumor cells.
    Roda JM; Parihar R; Magro C; Nuovo GJ; Tridandapani S; Carson WE
    Cancer Res; 2006 Jan; 66(1):517-26. PubMed ID: 16397268
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A novel human anti-TIGIT monoclonal antibody with excellent function in eliciting NK cell-mediated antitumor immunity.
    Han D; Xu Y; Zhao X; Mao Y; Kang Q; Wen W; Yu X; Xu L; Liu F; Zhang M; Cui J; Wang Z; Yang Z; Du P; Qin W
    Biochem Biophys Res Commun; 2021 Jan; 534():134-140. PubMed ID: 33341068
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Improvement of daratumumab- or elotuzumab-mediated NK cell activity by the bi-specific 4-1BB agonist, DARPin α-FAPx4-1BB: A preclinical study in multiple myeloma.
    Saltarella I; Link A; Lamanuzzi A; Reichen C; Robinson J; Altamura C; Melaccio A; Solimando AG; Ria R; Mariggiò MA; Vacca A; Frassanito MA; Desaphy JF
    Biomed Pharmacother; 2024 Jul; 176():116877. PubMed ID: 38850654
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Chimeric antigen receptor T cells secreting anti-PD-L1 antibodies more effectively regress renal cell carcinoma in a humanized mouse model.
    Suarez ER; Chang de K; Sun J; Sui J; Freeman GJ; Signoretti S; Zhu Q; Marasco WA
    Oncotarget; 2016 Jun; 7(23):34341-55. PubMed ID: 27145284
    [TBL] [Abstract][Full Text] [Related]  

  • 32. NK cells suppress CD8
    Chen T; Zhang T; Liu C; Wang C; Ding S; Shao Z; Fu R
    Cell Immunol; 2019 Jan; 335():6-14. PubMed ID: 30471872
    [TBL] [Abstract][Full Text] [Related]  

  • 33. NK Cells Restrain Spontaneous Antitumor CD8+ T Cell Priming through PD-1/PD-L1 Interactions with Dendritic Cells.
    Iraolagoitia XL; Spallanzani RG; Torres NI; Araya RE; Ziblat A; Domaica CI; Sierra JM; Nuñez SY; Secchiari F; Gajewski TF; Zwirner NW; Fuertes MB
    J Immunol; 2016 Aug; 197(3):953-61. PubMed ID: 27342842
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cocultures of human colorectal tumor spheroids with immune cells reveal the therapeutic potential of MICA/B and NKG2A targeting for cancer treatment.
    Courau T; Bonnereau J; Chicoteau J; Bottois H; Remark R; Assante Miranda L; Toubert A; Blery M; Aparicio T; Allez M; Le Bourhis L
    J Immunother Cancer; 2019 Mar; 7(1):74. PubMed ID: 30871626
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Blocking expression of inhibitory receptor NKG2A overcomes tumor resistance to NK cells.
    Kamiya T; Seow SV; Wong D; Robinson M; Campana D
    J Clin Invest; 2019 May; 129(5):2094-2106. PubMed ID: 30860984
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Engineered IL-21 Cytokine Muteins Fused to Anti-PD-1 Antibodies Can Improve CD8+ T Cell Function and Anti-tumor Immunity.
    Shen S; Sckisel G; Sahoo A; Lalani A; Otter DD; Pearson J; DeVoss J; Cheng J; Casey SC; Case R; Yang M; Low R; Daris M; Fan B; Agrawal NJ; Ali K
    Front Immunol; 2020; 11():832. PubMed ID: 32457754
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Receptors and lytic mediators regulating anti-tumor activity by the leukemic killer T cell line TALL-104.
    Brando C; Mukhopadhyay S; Kovacs E; Medina R; Patel P; Catina TL; Campbell KS; Santoli D
    J Leukoc Biol; 2005 Aug; 78(2):359-71. PubMed ID: 15937142
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The Inhibitory Receptor NKG2A Sustains Virus-Specific CD8⁺ T Cells in Response to a Lethal Poxvirus Infection.
    Rapaport AS; Schriewer J; Gilfillan S; Hembrador E; Crump R; Plougastel BF; Wang Y; Le Friec G; Gao J; Cella M; Pircher H; Yokoyama WM; Buller RM; Colonna M
    Immunity; 2015 Dec; 43(6):1112-24. PubMed ID: 26680205
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Immunotherapy targeting 4-1BB: mechanistic rationale, clinical results, and future strategies.
    Chester C; Sanmamed MF; Wang J; Melero I
    Blood; 2018 Jan; 131(1):49-57. PubMed ID: 29118009
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Therapeutic effect of CD137 immunomodulation in lymphoma and its enhancement by Treg depletion.
    Houot R; Goldstein MJ; Kohrt HE; Myklebust JH; Alizadeh AA; Lin JT; Irish JM; Torchia JA; Kolstad A; Chen L; Levy R
    Blood; 2009 Oct; 114(16):3431-8. PubMed ID: 19641184
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.